Scope and Patent Landscape for US Patent 5,453,446 (R(+)-N-propargyl-1-aminoindan for Parkinson’s disease)
US 5,453,446 is a US method-of-treatment patent with claims focused on administering the single stereoisomer R(+)-N-propargyl-1-aminoindan (and pharmaceutically acceptable salts) to treat Parkinson’s disease. The independent claim is broad as to patient population and route in principle, then narrows into specific administration routes (oral, rectal, transdermal, parenteral) and dosage ranges. Dependent claims add combination therapy concepts with decarboxylase inhibitors (carbidopa, benserazide) and with levodopa. The enforceable core is narrow to the defined compound and its salts, but broad in treatment method framing and route/dose sub-claims.
What are the key claims of US Patent 5,453,446 and what do they cover?
Independent claim coverage (Claim 1)
Claim 1 covers:
- A method of treating Parkinson’s disease
- by administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt
- effective to treat the Parkinson’s disease.
Legal scope implications
- Compound-limited: Infringement requires use of the specific active (R(+)-N-propargyl-1-aminoindan) or a salt. Products using other stereoisomers, racemates, or different propargyl-aminoindan analogs fall outside this claim.
- Method framing: “Treating” is a treatment step. That tends to support infringement theories aimed at prescribing, dispensing, or using a drug for Parkinson’s disease, depending on the jurisdiction’s treatment-use enforcement pathway.
- Dose not strictly limited in Claim 1: Dose is “an amount … effective,” leaving room for arguments about clinical effectiveness rather than a hard numeric limit.
Route and dosage sub-claim architecture
Claims 2–20 are structured as route-specific and dose-specific dependent claims, then combination-therapy dependents.
Route-specific claims
- Oral: Claim 2 (oral administration) plus dosage ranges in Claims 3–4
- Rectal: Claim 5 (rectal administration) plus dosage ranges in Claims 6–7
- Transdermal: Claim 8 (transdermal administration) plus dosage ranges in Claims 9–10
- Parenteral: Claim 11 (parenteral administration) plus concentration/dose in Claims 12–13
- Claim 1 is not explicitly route-limited, but the specification of dependent routes can still matter in claim construction and in how the patent holder characterizes the inventive concept.
Dosage numeric limits (value proposition for claim construction)
- Oral and rectal and transdermal share the same numeric ladder:
- 2 to 20 mg per daily dosage unit (Claims 3, 6, 9)
- 5 to 10 mg per daily dosage unit (Claims 4, 7, 10)
- Parenteral is written differently:
- 1 to 10 mg per mL per daily dosage unit (Claim 12)
- 2 to 5 mg per mL per daily dosage unit (Claim 13)
Practical infringement sensitivity
- If a competitor uses the same compound but delivers it outside the claimed numeric ranges, the dependent claims may not be infringed, while Claim 1 may still be asserted (because Claim 1 lacks numeric limits). That makes Claim 1 the likely “fallback” claim in litigation and settlements.
How do the dependent claims narrow the patent’s scope: oral, rectal, transdermal, parenteral
Oral administration claims
- Claim 2: oral administration
- Claim 3: 2 to 20 mg per daily dosage unit
- Claim 4: 5 to 10 mg per daily dosage unit
Rectal administration claims
- Claim 5: rectal administration
- Claim 6: 2 to 20 mg per daily dosage unit
- Claim 7: 5 to 10 mg per daily dosage unit
Transdermal administration claims
- Claim 8: transdermal administration
- Claim 9: 2 to 20 mg per daily dosage unit
- Claim 10: 5 to 10 mg per daily dosage unit
Parenteral administration claims
- Claim 11: parenteral administration
- Claim 12: 1 to 10 mg per mL per daily dosage unit
- Claim 13: 2 to 5 mg per mL per daily dosage unit
Key technical observation for enforcement
The patent treats route as a claim feature and also ties dosage ranges to route. That can matter if a generic or follow-on product uses:
- the same compound but a different route (e.g., oral vs transdermal), or
- a different dosing schedule or concentration formulation for parenteral delivery.
What combination-therapy claims exist in US 5,453,446 (carbidopa, benserazide, levodopa)?
Decarboxylase inhibitor combination
- Claim 14: further comprises administering a decarboxylase inhibitor effective to ensure L-Dopa uptake
- Claim 15: decarboxylase inhibitor is carbidopa
- Claim 16: decarboxylase inhibitor is benserazide
Levodopa combination
- Claim 17: further comprises administering levodopa in an amount relative to the amount of R(+)-N-propargyl-1-aminoindan effective to treat the disease
Redundant combination dependents
- Claims 18–20 restate the decarboxylase inhibitor pathway (Claim 18 + Claim 19 carbidopa + Claim 20 benserazide).
Scope meaning
- These dependents add an extra active drug step that can be a litigation differentiator.
- Infringement of these dependents typically requires both:
- administration of R(+)-N-propargyl-1-aminoindan (or salt), and
- concurrent administration of a decarboxylase inhibitor (carbidopa or benserazide) or levodopa, depending on the claim.
Design-around pressure
Competitors can attempt to avoid specific combination claim dependents by:
- not prescribing concurrent carbidopa/benserazide or not using levodopa, or
- using them but challenging whether the “effective to ensure L-Dopa uptake” or “effective relative amount” limitation is met.
What patents protect Parkinson’s treatment with R(+)-N-propargyl-1-aminoindan in the US?
Based only on the claim text provided, US 5,453,446 protects:
- a method of treating Parkinson’s disease with R(+)-N-propargyl-1-aminoindan (and salts),
- across multiple routes (oral/rectal/transdermal/parenteral),
- within route-specific dose ranges,
- and in combination regimens involving levodopa and/or decarboxylase inhibitors (carbidopa, benserazide).
No other US patent numbers, publication numbers, or assignees were provided with the prompt. Without those, a complete cross-patent landscape (priority chain, related continuations, continuation-in-part filings, overlapping claims, family members, or prosecution history) cannot be constructed accurately.
When does US 5,453,446 lose exclusivity? (expiration and term assessment)
The prompt provides the patent number and claims but does not provide:
- filing date,
- priority date,
- whether the patent is subject to PTA/PTE,
- whether it is a continuation or has multiple priority events.
Without those data, the expiration timeline cannot be computed to an exact date.
Is US 5,453,446 likely to be listed in the FDA Orange Book? What does that imply?
US 5,453,446 is a method-of-treatment patent. Whether it appears in the Orange Book depends on:
- whether it is tied to an approved drug product with an active ingredient matching R(+)-N-propargyl-1-aminoindan (or salt) and
- whether the patent holder submitted it for listing (and on what basis: method of use).
No FDA listing data, NDCs, application numbers, or Orange Book entries were provided. Therefore, Orange Book status cannot be determined from the prompt.
What Paragraph IV or biosimilar-style risks exist for this patent?
This patent is not a biologic; it is a small-molecule method-of-treatment patent directed to a specific active ingredient. The typical “biosimilar” pathway does not apply.
Paragraph IV certification frameworks depend on the existence of an ANDA AND a listed patent in the Orange Book with a relevant method-of-use claim. No ANDA/applications or Orange Book linkage were provided, so Paragraph IV risk assessment cannot be mapped precisely to this patent.
Which generic entry scenarios could infringe US 5,453,446?
Infringement risk scenarios depend on whether the generic:
- uses the same stereoisomer (R(+)-N-propargyl-1-aminoindan),
- uses a pharmaceutically acceptable salt that falls within the claim language, and
- the method in practice is “effective to treat Parkinson’s disease.”
High-risk scenario
A generic drug identical in active ingredient (R(+)-N-propargyl-1-aminoindan) and uses the drug to treat Parkinson’s disease, including when:
- oral dosing is within 2–20 mg or 5–10 mg per daily dosage unit, or
- transdermal dosing is within the analogous daily mg ranges, or
- parenteral dosing uses 1–10 mg/mL or 2–5 mg/mL per daily dosage unit.
Moderate-risk scenario
Use of the same active but:
- dosing is outside the dependent dose ranges.
Claim 1 may still be asserted because it does not include numeric dose thresholds.
Lower-risk scenario
A product avoids the claim by:
- using a different stereochemical form (e.g., non-R(+)),
- using a different active ingredient not captured by “R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof,” or
- avoiding the specific combination dependents (carbidopa/benserazide/levodopa).
This would not automatically avoid Claim 1 if the method of treating Parkinson’s is still performed with the protected active.
How strong are the enforceability levers in US 5,453,446 (claim breadth and vulnerability)
Strength drivers from the claim set:
- Clear active ingredient definition: R(+)-N-propargyl-1-aminoindan and salts are explicit.
- Broad treatment framing: Claim 1 is not tethered to a particular patient phenotype, disease stage, or specific endpoint beyond “effective to treat Parkinson’s disease.”
- Multiple dependent anchors: Route and dose dependent claims provide multiple “infringement pathways” depending on how accused products are used.
Potential vulnerability drivers (structured claim-level, not legal validity commentary):
- Reliance on dose/route for dependents: If practical regimens are outside numeric limitations, dependence claims may not apply.
- Dependence on combination co-administration for dependents: Combination dependents require the additional drug(s) and the functional language (effective to ensure L-Dopa uptake; levodopa relative amount).
Key Takeaways
- US 5,453,446 is a compound-defined method-of-treatment patent: it covers administering R(+)-N-propargyl-1-aminoindan (or salts) to treat Parkinson’s disease.
- Claim 1 is broad on dose and route; Claims 2–13 add route-specific and numeric dose/concentration limitations for oral, rectal, transdermal, and parenteral use.
- Claims 14–16 cover combination regimens with decarboxylase inhibitors, specifically carbidopa and benserazide.
- Claims 17 and 18–20 cover combination therapy also involving levodopa and decarboxylase inhibitors.
- A litigation or licensing strategy should treat Claim 1 as the central coverage claim, with dependent claims providing additional leverage based on the accused dosing route and numeric regimen.
FAQs
1) Does US 5,453,446 require using carbidopa or benserazide to infringe?
No. Carbidopa/benserazide appear only in dependent claims (Claims 14–16 and 18–20). Claim 1 does not require them.
2) If a product uses the same compound but delivers outside 5–10 mg daily, does it avoid infringement?
It may avoid the dependent dose-range claims (Claims 4, 7, 10, and related parenteral dependents), but it does not necessarily avoid Claim 1, which has no numeric dose limitation.
3) Are transdermal formulations covered even if the claimed daily mg range is not used?
Transdermal coverage exists at the dependent claim level (Claims 8–10). If the daily dosage unit falls outside 2–20 mg or 5–10 mg ranges, those dependents may not apply, while Claim 1 may still cover treatment by administering an effective amount.
4) Can a challenger design around by using a different stereoisomer?
The claims are limited to R(+)-N-propargyl-1-aminoindan. A different stereoisomer or racemate is not captured by the literal wording provided.
5) Is this patent a formulation patent or a dosing method patent?
It is a method-of-treatment patent. The claim set provided is directed to administering a dose via specified routes, not a formulation composition claim.
References
No external sources were provided in the prompt to cite.
